Literature DB >> 7695465

Long QT syndrome during high-dose cisapride.

S Bran1, W A Murray, I B Hirsch, J P Palmer.   

Abstract

The gastrointestinal prokinetic drug, cisapride, is widely used for the treatment of diabetic gastroparesis and disorders of gastrointestinal motility. We present a case of acquired QT prolongation, syncope, and nonsustained ventricular tachycardia associated with high doses of cisapride.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7695465

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


  22 in total

1.  Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes.

Authors:  H B Nuss; E Marbán; D C Johns
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 2.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

3.  Unexplained Nausea and Vomiting.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

4.  Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.

Authors:  J A Zix; H F Geerdes-Fenge; M Rau; J Vöckler; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 5.  Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures.

Authors:  J R Malagelada; E Distrutti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

6.  Effects of cisapride on QTc interval in neonates.

Authors:  S Bernardini; D S Semama; F Huet; C Sgro; J B Gouyon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-11       Impact factor: 5.747

Review 7.  Cisapride. Drug interactions of clinical significance.

Authors:  T A Bedford; D J Rowbotham
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

8.  Effect of oral erythromycin on gastric and small bowel transit time of capsule endoscopy.

Authors:  Wai K Leung; Francis K L Chan; Sara S L Fung; Mei-Yin Wong; Joseph J Y Sung
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

Review 9.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 10.  Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.

Authors:  William L Hasler; Philip Schoenfeld
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.